San Francisco, United States
Shennon Biotechnologies, founded in 2021, is revolutionizing the biotechnology and life sciences industries with its cutting-edge platform that profiles immune cells at the single-cell level, offering unparalleled throughput and accuracy. This innovation addresses a significant hurdle in the field of immunotherapy, enabling the development of more effective therapies for solid tumors and autoimmune diseases.
Based in the biotech hub of San Francisco, adjacent to UCSF Mission Bay, Shennon Biotechnologies is positioning itself as a leader in the field of immunotherapy research. The proprietary technology developed by the company allows for the functional profiling of immune cells and their antigens, advancing therapeutic strategies.
The startup has garnered significant financial backing, with a recent $13.00M Seed Round investment completed on March 13, 2023, supported by investors like AV8 Ventures, DCVC, Foundation Capital, Jasper Lau, and Mei Z. Such endorsements highlight the potential and confidence in Shennon Biotechnologies' mission to enhance treatments for human diseases.
